Phase II study evaluating Holmium-166 TARE followed by maIntenance Therapy in liver limited unresectable colorectal cancer patients after first-lIne chemotherapy and target agents: The HAITI study.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505356-22-00

Acronym

HAITI

Enrollment

Registered

2023-12-18

Start date

2024-03-13

Completion date

2025-11-14

Last updated

2023-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver limited unresectable colorectal cancer

Brief summary

Progression-free survival (PFS) Rate at 9- and 8-months for Cohort A and B, respectively

Detailed description

Overall Toxicity rate, G3/4 Toxicity rate, Post-treatment DCR, Progression free survival (PFS), Overall Survival (OS), Dose-response relationships, Quality of Life

Interventions

DRUGCAPECITABINE

DRUGBEVACIZUMAB

DRUGPANITUMUMAB

DRUGCETUXIMAB

DRUGFLUOROURACIL

DRUGCALCIUM LEVOFOLINATE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-free survival (PFS) Rate at 9- and 8-months for Cohort A and B, respectively	—

Secondary

Measure	Time frame
Overall Toxicity rate, G3/4 Toxicity rate, Post-treatment DCR, Progression free survival (PFS), Overall Survival (OS), Dose-response relationships, Quality of Life	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026